ExodusPoint Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History

ExodusPoint Capital Management’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-109,227	Closed	-$493K	–	1719
2025 Q2	$493K	Buy	109,227 +12,882	+13%	+$57.5K	﹤0.01%	1157
2025 Q1	$447K	Buy	+96,345	New	+$591K	﹤0.01%	1131
2024 Q4	–	Sell	-393,586	Closed	-$2.09M	–	1706
2024 Q3	$2.09M	Buy	393,586 +86,267	+28%	+$435K	0.01%	721
2024 Q2	$1.15M	Buy	307,319 +42,041	+16%	+$214K	0.01%	974
2024 Q1	$1.87M	Buy	265,278 +35,474	+15%	+$210K	0.01%	734
2023 Q4	$1.3M	Sell	229,804 -389,444	-63%	-$1.53M	0.01%	723
2023 Q3	$2.97M	Sell	619,248 -50,247	-8%	-$323K	0.03%	541
2023 Q2	$4.59M	Buy	669,495 +407,902	+156%	+$2.64M	0.04%	478
2023 Q1	$2.04M	Buy	+261,593	New	+$1.82M	0.02%	869

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

ExodusPoint Capital Management's GLUE Position: Q3 2025 in Review

ExodusPoint Capital Management sold out of Monte Rosa Therapeutics (GLUE) in Q3 2025, closing a stake of 109,227 shares — an estimated $493K sold.

ExodusPoint Capital Management first reported a position in GLUE in Q1 2023 and held it in 9 quarters. The position peaked at $4.59M in Q2 2023. 129 funds tracked by Wall St. Rank hold GLUE as of Q3 2025.

ExodusPoint Capital Management reported no remaining Monte Rosa Therapeutics position as of Q3 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 109,227 Monte Rosa Therapeutics shares in Q3 2025, an estimated $493K.
ExodusPoint Capital Management first reported a position in Monte Rosa Therapeutics in Q1 2023 and held it in 9 quarters.
ExodusPoint Capital Management's Monte Rosa Therapeutics position peaked at $4.59M in Q2 2023.
129 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.